+
For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact userservices@mhprofessional.com.
++
Content Update
June 24, 2024
New First-Line Role for SGLT2 Inhibitors and Updates across the Spectrum of Heart Failure by Left Ventricular Ejection Fraction: In 2022, the American College of Cardiology/American Heart Association/Heart Failure Society of America released a guideline which adopts new heart failure (HF) syndrome nomenclature, expands first-line guideline-directed medical therapies (GDMT) to include sodium-glucose cotransporter-2 (SGLT2) inhibitors, and provides pharmacotherapy recommendations for HF with preserved ejection fraction (HFpEF) and mildly-reduced ejection fraction (HFmrEF). Studies indicate the benefit with SGLT2 inhibitors is consistent across the full spectrum of HF syndromes by LVEF. Therefore, the guidelines recommend SGLT2 inhibitors be considered as first-line therapy for patients with HFpEF and HFmrEF. The role of sacubitril/valsartan in patients with HF and LVEF greater than 40% (0.40) is also discussed.
++
LEARNING OBJECTIVES
Upon completion of the chapter, the reader will be able to:
Classify heart failure (HF) syndrome types into HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), HF with mid-range ejection fraction (HFmrEF), and HF with recovered ejection fraction (HFrecEF).
Differentiate between the common underlying etiologies of HF, including ischemic, nonischemic, and idiopathic causes.
Describe the pathophysiology of HF as it relates to neurohormonal activation of the renin-angiotensin-aldosterone system, sympathetic nervous system, and endogenous counterregulatory vasodilatory peptide systems.
Identify signs and symptoms of HF and classify a given patient by New York Heart Association Functional Classification and American College of Cardiology/American Heart Association Heart Failure Stage.
Discuss and modify the goals of therapy for a patient with acute and/or chronic HF.
Create a strategy for the nonpharmacologic management of a patient with HF that includes patient education.
Develop an evidence-based pharmacologic treatment and monitoring plan for a patient with chronic HFrEF.
Design a pharmacologic treatment and monitoring plan for a patient with acute HF.
Formulate a therapeutic management plan for a patient with HFpEF.
++
Heart failure (HF) is a syndrome defined as the inadequate ability of the heart to pump enough blood to meet the blood flow and metabolic demands of the body.1 HF is most commonly a result of low cardiac output (CO) secondary to impaired cardiac function. High-output HF is characterized by an inordinate increase in the body’s metabolic demands that outpaces an increase in CO of a generally normally functioning heart. The term heart failure refers to low-output HF for the purposes of this chapter.
++
HF can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to eject or fill with blood.1 Apart from the clinical syndrome, it is commonly characterized by assessment of left ventricular (LV) function. Impairment in ventricular contraction (systolic dysfunction) and/or ventricular filling (diastolic dysfunction) can result in a similar decrease in CO. Ejection fraction (EF) is the fraction ...